Question:

I believe that part of the answer in last week’s posting is incorrect. You stated that code Q5102 (which describes both currently available versions of infliximab biosimilars) will be discontinued and replaced with codes 5102 and 5014. Although it’s true Q5102 will be discontinued March 31, 2018, I don’t think the replacement codes are correct. Can you provide the right codes?

Answer:

Thank you for calling this error to our attention. Effective for claims with dates of service on or after April 1, 2018, HCPCS level II code Q5102 (injection, infliximab, biosimilar, 10 mg) will be replaced with the following:

Q5103 Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg
Q5014 Injection, infliximab-abda, biosimilar, (renflexis), 10 mg

This question was answered in an edition of our Laboratory Compliance Manager. For more hot topics relating to laboratory services, please view our store, or call us at 1.800.252.1578 ext. 2.

Facebook
Twitter
LinkedIn
Email
Print

CPT® copyright 2021 American Medical Association (AMA). All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

CPT is a registered trademark of the American Medical Association.